SPOTLIGHT: Crucell forges pact with Sanofi

Crucell stands to gain $112 million in a new development pact with Sanofi Pasteur, which wants to use its antibodies for a rabies vaccine. Report

Suggested Articles

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.